生命科学资讯

GSK pays $2.2B to buy Rapt for its phase 2-stage food allergy challenger to Xolair

ARPA-H director eyes future beyond vaccines, ‘winning the biotech race’ against China

Abbott, AtaCor join forces on extravascular defibrillator implant

J&J, Isomorphic sign research deal for AI-made molecules

Agilent Technologies (A) Initiated with "Buy" Rating by HSBC | A Stock News - GuruFocus

GSK makes $2.2B deal for RAPT and its food allergy candidate

Illumina Inc. (ILMN) Shares See Target Boost as Analysts See Potential 2026 Upside - Insider Monkey

The patient retention crisis is happening before enrollment even begins

When every day counts: Building CRO partnerships on a foundation of trust, care and precision

HSBC initiates coverage on Agilent stock with Buy rating, $180 target - Investing.com

Exciva raises $59M Series B to fund Phase 2 test of Alzheimer’s agitation drug

Illumina: What Is Next In This Sequence? (NASDAQ:ILMN) - Seeking Alpha

The Bull Case For Illumina (ILMN) Could Change Following Its Billion Cell Atlas Pharma Alliance - Yahoo Finance Singapore

Nucleotide Market Is Going to Boom | Agilent Technologies • Bio-Rad Laboratories • QIAGEN - openPR.com

Is Waters Corporation the Quiet Wall Street Cheat Code Everyone’s Sleeping On? - AD HOC NEWS

Is Waters Corporation the Quiet Wall Street Cheat Code Everyone’s Sleeping On? - AD HOC NEWS

Profit Recap: Is Agilent Technologies Inc showing insider buying - Quarterly Earnings Summary & AI Driven Stock Price Forecasts - baoquankhu1.vn

Thermo Fisher Scientific Inc. (TMO): A Bull Case Theory - Insider Monkey

FDA Grants RMAT Designation to iRegene’s NouvNeu001, Cementing its Lead as the World’s First iPSC Therapy with Both FTD and RMAT Recognitions

AstraZeneca pens $630M pact to secure remaining rights to armored CAR-T from AbelZeta